Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2000 7
2006 1
2012 2
2013 5
2014 4
2015 4
2016 4
2017 4
2018 6
2019 28
2020 60
2021 95
2022 83
2023 122
2024 149
2025 143
2026 49

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

674 results

Results by year

Filters applied: . Clear all
Page 1
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, Thompson PD, Libby P, Cho L, Plutzky J, Bays HE, Moriarty PM, Menon V, Grobbee DE, Louie MJ, Chen CF, Li N, Bloedon L, Robinson P, Horner M, Sasiela WJ, McCluskey J, Davey D, Fajardo-Campos P, Petrovic P, Fedacko J, Zmuda W, Lukyanov Y, Nicholls SJ; CLEAR Outcomes Investigators. Nissen SE, et al. N Engl J Med. 2023 Apr 13;388(15):1353-1364. doi: 10.1056/NEJMoa2215024. Epub 2023 Mar 4. N Engl J Med. 2023. PMID: 36876740 Clinical Trial.
The mean LDL cholesterol level at baseline was 139.0 mg per deciliter in both groups, and after 6 months, the reduction in the level was greater with bempedoic acid than with placebo by 29.2 mg per deciliter; the observed difference in the percent reductions was 21. …
The mean LDL cholesterol level at baseline was 139.0 mg per deciliter in both groups, and after 6 months, the reduction in the level was gre …
Bempedoic Acid: for Whom and When.
Ruscica M, Sirtori CR, Carugo S, Banach M, Corsini A. Ruscica M, et al. Curr Atheroscler Rep. 2022 Oct;24(10):791-801. doi: 10.1007/s11883-022-01054-2. Epub 2022 Jul 28. Curr Atheroscler Rep. 2022. PMID: 35900636 Free PMC article. Review.
Bempedoic acid antagonizes ATP citrate-lyase, a cytosolic enzyme upstream of HMGCoA reductase which is the rate-limiting step of cholesterol biosynthesis. ...Bempedoic acid does not lead to the risk of new-onset diabetes, and moderately improves the gl …
Bempedoic acid antagonizes ATP citrate-lyase, a cytosolic enzyme upstream of HMGCoA reductase which is the rate-limiting step …
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, Robinson PL, Ballantyne CM; CLEAR Harmony Trial. Ray KK, et al. N Engl J Med. 2019 Mar 14;380(11):1022-1032. doi: 10.1056/NEJMoa1803917. N Engl J Med. 2019. PMID: 30865796 Free article. Clinical Trial.
BACKGROUND: Short-term studies have shown that bempedoic acid, an inhibitor of ATP citrate lyase, reduces levels of low-density lipoprotein (LDL) cholesterol. Data are limited regarding the safety and efficacy of bempedoic acid treatment in long-term s …
BACKGROUND: Short-term studies have shown that bempedoic acid, an inhibitor of ATP citrate lyase, reduces levels of low-densit …
Bempedoic Acid.
[No authors listed] [No authors listed] 2025 Aug 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2025 Aug 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 33104321 Free Books & Documents. Review.
The amounts of bempedoic acid and its active metabolite are very low, but there is no published experience with bempedoic acid during breastfeeding. If a mother requires bempedoic acid, it is not a reason to discontinue breastfeeding. An …
The amounts of bempedoic acid and its active metabolite are very low, but there is no published experience with bempedoic …
Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, Stroes ES, MacDougall D, Zhao X, Catapano AL. Ballantyne CM, et al. Eur J Prev Cardiol. 2020 Apr;27(6):593-603. doi: 10.1177/2047487319864671. Epub 2019 Jul 29. Eur J Prev Cardiol. 2020. PMID: 31357887 Free PMC article. Clinical Trial.
Patients were randomly assigned (2:2:2:1) to treatment with the fixed-dose combination, bempedoic acid 180 mg, ezetimibe 10 mg or placebo added to stable background statin therapy for 12 weeks. ...In this trial, fixed-dose combination treatment had a generally simil …
Patients were randomly assigned (2:2:2:1) to treatment with the fixed-dose combination, bempedoic acid 180 mg, ezetimibe 10 mg …
Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, Lalwani ND, Patel PM, Zhao X, Duell PB. Goldberg AC, et al. JAMA. 2019 Nov 12;322(18):1780-1788. doi: 10.1001/jama.2019.16585. JAMA. 2019. PMID: 31714986 Free PMC article. Clinical Trial.

At baseline, mean LDL-C level was 120.4 (SD, 37.9) mg/dL. Bempedoic acid lowered LDL-C levels significantly more than placebo at week 12 (-15.1% vs 2.4%, respectively; difference, -17.4% [95% CI, -21.0% to -13.9%]; P < .001). ...Common adverse events included nas

…
At baseline, mean LDL-C level was 120.4 (SD, 37.9) mg/dL. Bempedoic acid lowered LDL-C levels significantly more than placebo …
Role of Bempedoic Acid in Clinical Practice.
Ballantyne CM, Bays H, Catapano AL, Goldberg A, Ray KK, Saseen JJ. Ballantyne CM, et al. Cardiovasc Drugs Ther. 2021 Aug;35(4):853-864. doi: 10.1007/s10557-021-07147-5. Epub 2021 Apr 5. Cardiovasc Drugs Ther. 2021. PMID: 33818688 Free PMC article. Review.
Bempedoic acid is generally well tolerated with no clinically meaningful increase in muscle-related symptoms relative to placebo, even in patients taking maximally tolerated statins. ...The potential for a reduced incidence of major cardiovascular events with bem …
Bempedoic acid is generally well tolerated with no clinically meaningful increase in muscle-related symptoms relative to place …
Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients.
Nissen SE, Menon V, Nicholls SJ, Brennan D, Laffin L, Ridker P, Ray KK, Mason D, Kastelein JJP, Cho L, Libby P, Li N, Foody J, Louie MJ, Lincoff AM. Nissen SE, et al. JAMA. 2023 Jul 11;330(2):131-140. doi: 10.1001/jama.2023.9696. JAMA. 2023. PMID: 37354546 Free PMC article.
IMPORTANCE: The effects of bempedoic acid on cardiovascular outcomes in statin-intolerant patients without a prior cardiovascular event (primary prevention) have not been fully described. ...CONCLUSIONS: In a subgroup of high-risk primary prevention patients, bem …
IMPORTANCE: The effects of bempedoic acid on cardiovascular outcomes in statin-intolerant patients without a prior cardiovascu …
Bempedoic Acid.
[No authors listed] [No authors listed] 2023 Jul 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2023 Jul 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 37487014 Free Books & Documents. Review.
Bempedoic acid is a small molecule inhibitor of adenosine triphosphate-citrate lyase that is used as a cholesterol lowering agent in patients with hypercholesterolemia and high risk or with known atherosclerotic cardiovascular disease who fail to have an adequate re …
Bempedoic acid is a small molecule inhibitor of adenosine triphosphate-citrate lyase that is used as a cholesterol lowering ag …
[Bempedoic Acid].
Wagner M, Leefmann J, Künzel SR, Schmidt MM, El-Armouche A. Wagner M, et al. Dtsch Med Wochenschr. 2021 Apr;146(8):552-558. doi: 10.1055/a-1136-4356. Epub 2021 Apr 14. Dtsch Med Wochenschr. 2021. PMID: 33853173 Review. German.
ATP-Citrate-Lyase is a key enzyme of cholesterol biosynthesis. Its liver-specific inhibition by the bempedoic acid opens new possibilities to effectively escalate a cholesterol-lowering therapy while avoiding muscle-related side effects. ...
ATP-Citrate-Lyase is a key enzyme of cholesterol biosynthesis. Its liver-specific inhibition by the bempedoic acid opens new p …
674 results